New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
10:29 EDTJNJ, SNY, ABBVJohnson & Johnson advances after Jefferies upgrade
Shares of Johnson & Johnson (JNJ) are climbing after Jefferies upgraded its rating on the stock. WHAT'S NEW: Johnson & Johnson's stock has reached "a great entry point," Jefferies analyst Jeffrey Holford wrote in a note to investors. The execution of the company's pharmaceutical business continues to be excellent, Holford believes. The unit's growth is being driven by the company's Zytiga prostate cancer treatment and its Xarelto drug which is used to reduce the risk of stroke and blood clots in people with atrial fibrillation, as well as another drug, Invokana, which improves glycemic control in some diabetes patients, the analyst contended. In the future Johnson & Johnson will also be helped by some of its new products, and investors are under-appreciating this upcoming catalyst, added Holford. Meanwhile, the company's consumer business should rebound, as its manufacturing issues should no longer have much of an impact on revenue, the analyst stated. The analyst is also more upbeat on the company's ibrutnib treatment for mantle cell lymphoma He upgraded the stock to Buy from Hold and raised his price target on the shares to $108 from $102. WHAT'S NOTABLE: Sanofi (SNY) is Holford's top European pick in the pharmaceutical market, while AbbVie (ABBV) is his top American pick. PRICE ACTION: In mid-morning trading, Johnson & Johnson rose 70c, or 0.74%, to $94.84.
News For JNJ;SNY;ABBV From The Last 14 Days
Check below for free stories on JNJ;SNY;ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2014
07:46 EDTJNJJohnson & Johnson reports Q1 adjusted EPS $1.54, consensus $1.48
Reports Q1 revenue $18.1B, consensus $18.0B
06:32 EDTJNJ, SNYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
17:31 EDTABBVAbbVie stock could reach $55, Barron's says
Subscribe for More Information
15:17 EDTJNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
13:25 EDTJNJEarnings Preview: J&J looking for another strong performance in pharmaceuticals
Subscribe for More Information
10:02 EDTJNJOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:45 EDTABBVAbbVie defended at BMO Capital
Subscribe for More Information
05:56 EDTJNJJohnson & Johnson downgraded to Hold from Buy at Jefferies
Jefferies downgraded its rating on Johnson & Johnson (JNJ) to Hold citing the recent outperformance of shares. The firm keeps a $105 price target for the stock.
April 12, 2014
19:23 EDTABBVEnanta reports detailed results from Turquoise ll study
Enanta Pharmaceuticals (ENTA) announced that detailed results from AbbVie’s (ABBV) pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation at the International Liver Congress, ILC, which is the 49th Annual Meeting of the European Association for the Study of the Liver, EASL. Results from the TURQUOISE-II study were featured in the ILC press conference and were published on-line in the New England Journal of Medicine. The TURQUOISE-II study reports results from AbbVie’s investigational three direct-acting antiviral regimen containing ABT-450, Enanta’s lead protease inhibitor discovered through Enanta’s collaboration with AbbVie. The regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's three direct-acting antiviral regimen with ribavirin, RBV, in adult patients with genotype 1, GT1, chronic hepatitis C virus, HCV, infection with compensated liver cirrhosis. Patients achieved sustained virologic response rates 12 weeks post-treatment, SVR12, of 91.8% and 95.9% in the 12-week and 24-week treatment arms, respectively. Patients in the study were either new to therapy or treatment-experienced, failed previous treatment with pegylated interferon and RBV.
April 11, 2014
18:44 EDTJNJJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information
07:06 EDTSNYVIVUS announces avanafil clinical data presentation
Subscribe for More Information
05:27 EDTABBVEnanta announces results for partner AbbVie's HCV studies
Subscribe for More Information
05:24 EDTABBVAbbVie announces 96% sustained virologic response rates in HCV study
Subscribe for More Information
April 9, 2014
11:43 EDTABBVGilead defended by analysts after recent pullback
Subscribe for More Information
07:23 EDTJNJEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTSNYReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
07:09 EDTJNJJohnson & Johnson outlook positive into Q1 results, says Bernstein
Bernstein expects Johnson & Johnson's Q1 EPS to come in slightly above the consensus estimate, with strength in pharmaceuticals more than offsetting lackluster Medical Devices & Diagnostics growth, according to the firm. Bernstein keeps an Outperform rating on the stock.
April 8, 2014
11:03 EDTSNYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
07:26 EDTJNJElsevier Business Intelligence to hold a conference
Subscribe for More Information
April 7, 2014
05:28 EDTSNYGenzyme to resubmit Lemtrada application for FDA review
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use